Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 7/20 | 0.55 |
| ▸ | IL1B | P01584 | 8/20 | 0.41 |
| ▸ | TNF | P01375 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29326703 | 0.84 | NLRP3 (0.53) | NLRP3IL1BTNFKCNH2CRHR1 | |
| SCHEMBL29326657 | 0.84 | NLRP3 (0.60) | NLRP3IL1BTNFKCNH2CRHR1 | |
| SCHEMBL29326352 | 0.84 | NLRP3 (0.62) | NLRP3IL1BTNFKCNH2CRHR1 | |
| SCHEMBL29326373 | 0.83 | NLRP3 (0.54) | NLRP3IL1BTNFKCNH2MAPK14 | |
| SCHEMBL29326347 | 0.83 | NLRP3 (0.59) | NLRP3IL1BTNFKCNH2CRHR1 | |
| SCHEMBL29326652 | 0.83 | NLRP3 (0.56) | NLRP3IL1BTNFKCNH2 | |
| SCHEMBL29326589 | 0.82 | NLRP3 (0.58) | NLRP3IL1BTNFKCNH2CRHR1 | |
| SCHEMBL29326394 | 0.82 | NLRP3 (0.58) | NLRP3IL1BTNFKCNH2CRHR1 | |
| SCHEMBL29326837 | 0.82 | NLRP3 (0.60) | NLRP3IL1BTNFKCNH2CRHR1 | |
| SCHEMBL25857462 | 0.82 | NLRP3 (0.62) | NLRP3IL1BTNFKCNH2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | NLRP3 1/4885IL1B 11/4885TNF 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.